US Drug Recall Register
Class II · Moderate risk Terminated Initiated Sep 11, 2018 (8 years ago)

Lamotrigine Extended-Release Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.

What was recalled

Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured in INDIA, For: TORRENT PHARMA INC., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920. NDC: 13668-342-30

Recalling firm
Torrent Pharma Inc.
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1204-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Lamotrigine recalls

See all
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Labeling: Label Error on Declared Strength

AVKARE Inc. NDC 42291-367-10 D-1329-2022
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Presence of Foreign Substance consistent with granules from desiccant packs used during storage

AVKARE Inc. NDC 42291-368-60 D-1289-2020
Class III · Low risk Terminated

Lamotrigine Tablets

Reason Presence of Foreign Substance visually consistent with the silica granules present in the desiccant packs utilized during storage of the product.

Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-247-97 D-1281-2020
Class I · High risk Terminated

Lamotrigine Tablets

Reason Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Taro Pharmaceuticals U.S.A., Inc. NDC 51672-4131-1 D-0833-2020